JP6510033B2 - 三次元複合細胞凝集体モデル並びにその製造方法及び応用 - Google Patents
三次元複合細胞凝集体モデル並びにその製造方法及び応用 Download PDFInfo
- Publication number
- JP6510033B2 JP6510033B2 JP2017509728A JP2017509728A JP6510033B2 JP 6510033 B2 JP6510033 B2 JP 6510033B2 JP 2017509728 A JP2017509728 A JP 2017509728A JP 2017509728 A JP2017509728 A JP 2017509728A JP 6510033 B2 JP6510033 B2 JP 6510033B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cad
- fusion protein
- dimensional
- microspheres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims description 134
- 239000004005 microsphere Substances 0.000 claims description 70
- 108020001507 fusion proteins Proteins 0.000 claims description 50
- 102000037865 fusion proteins Human genes 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000000905 Cadherin Human genes 0.000 claims description 30
- 108050007957 Cadherin Proteins 0.000 claims description 30
- 210000000130 stem cell Anatomy 0.000 claims description 30
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 21
- 239000011165 3D composite Substances 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 13
- 230000006698 induction Effects 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 7
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 7
- 238000010353 genetic engineering Methods 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 230000024245 cell differentiation Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 108091006058 immobilized fusion proteins Proteins 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000012835 hanging drop method Methods 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 10
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002242 embryoid body Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000984015 Homo sapiens Cadherin-1 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000677 aggregate cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 102000047933 human CDH1 Human genes 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100028906 Catenin delta-1 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920004943 Delrin® Polymers 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 101000984025 Mus musculus Cadherin-1 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 108010031971 delta catenin Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510072086.3A CN104651300B (zh) | 2015-02-11 | 2015-02-11 | 一种三维复合细胞聚集体模型及其制备方法与应用 |
| CN201510072086.3 | 2015-02-11 | ||
| PCT/CN2016/073472 WO2016127908A1 (zh) | 2015-02-11 | 2016-02-04 | 一种三维复合细胞聚集体模型及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017532008A JP2017532008A (ja) | 2017-11-02 |
| JP6510033B2 true JP6510033B2 (ja) | 2019-05-08 |
Family
ID=53242949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017509728A Active JP6510033B2 (ja) | 2015-02-11 | 2016-02-04 | 三次元複合細胞凝集体モデル並びにその製造方法及び応用 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6510033B2 (zh) |
| CN (1) | CN104651300B (zh) |
| WO (1) | WO2016127908A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651300B (zh) * | 2015-02-11 | 2018-10-12 | 南开大学 | 一种三维复合细胞聚集体模型及其制备方法与应用 |
| CN105999423A (zh) * | 2016-07-21 | 2016-10-12 | 南开大学 | 一种多孔细胞外基质支架制备技术 |
| CN106581763A (zh) * | 2016-12-28 | 2017-04-26 | 溯源生命科技股份有限公司 | 一种干细胞人微型器官的制备方法 |
| CN109666630A (zh) * | 2017-10-17 | 2019-04-23 | 澳门大学 | 多能干细胞分化为间充质干细胞的方法及其培养基和应用 |
| US20210047612A1 (en) * | 2018-03-06 | 2021-02-18 | Epibone, Inc. | Injectable off-the- shelf cartilage, tendon, and ligament repair compositions and methods of use |
| CN108753692B (zh) * | 2018-05-03 | 2021-09-28 | 佛山科学技术学院 | 一种鸡胚原始生殖细胞的3d培养方法 |
| CN109337857B (zh) * | 2018-06-20 | 2022-04-19 | 南开大学 | 融合蛋白E-钙粘素-Fc、VE-钙粘素-Fc和VEGF-Fc的用途 |
| CN111175112A (zh) * | 2020-01-13 | 2020-05-19 | 浙江卫未生物医药科技有限公司 | 一种改良的微载体活细胞荧光染色方法 |
| CN111705036A (zh) * | 2020-06-30 | 2020-09-25 | 山东省医药生物技术研究中心（山东省病毒研究所） | 一种基于Collagel凝胶支架法三维培养纤维环源干细胞的方法 |
| CN115040695B (zh) * | 2021-03-09 | 2023-10-13 | 南开大学 | 一种基于VE-cad-Fc/N-cad-Fc的融合蛋白活性界面的应用 |
| CN113201525B (zh) * | 2021-04-12 | 2023-03-21 | 清华大学深圳国际研究生院 | 干细胞微球组及干细胞的体外扩增方法和应用 |
| CN114703129A (zh) * | 2022-03-09 | 2022-07-05 | 唐颐惠康干细胞产业平台(天津)有限公司 | 一种无酶化3d培养与扩增治疗性间充质干细胞的方法 |
| CN115322953A (zh) * | 2022-08-15 | 2022-11-11 | 中国医学科学院生物医学工程研究所 | 一种用于细胞三维培养的高效接种方法及其应用 |
| CN115572709A (zh) * | 2022-10-18 | 2023-01-06 | 中晶生物技术股份有限公司 | 三维培养间充质干细胞微球在制备脱发修复与再生药物或制剂中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1734112B1 (en) * | 2004-03-23 | 2017-08-23 | Toshihiro Akaike | Method of proliferating pluripotent stem cell |
| CN101463090B (zh) * | 2009-01-20 | 2011-06-29 | 中国人民解放军第三军医大学 | 纤连蛋白与钙粘附蛋白-11的融合蛋白、制备方法及应用 |
| CN102286422B (zh) * | 2011-06-22 | 2013-03-27 | 南开大学 | 一种用于体外细胞共培养的复合微囊模型 |
| JP6139054B2 (ja) * | 2011-12-19 | 2017-05-31 | ソマール株式会社 | 細胞培養基材、およびそれを用いた細胞培養方法並びに多能性幹細胞の分化誘導方法 |
| TWI719468B (zh) * | 2012-07-24 | 2021-02-21 | 日商日產化學股份有限公司 | 培養基組成物、其用途、細胞或組織之培養方法及細胞或組織培養物 |
| CN104651300B (zh) * | 2015-02-11 | 2018-10-12 | 南开大学 | 一种三维复合细胞聚集体模型及其制备方法与应用 |
-
2015
- 2015-02-11 CN CN201510072086.3A patent/CN104651300B/zh active Active
-
2016
- 2016-02-04 WO PCT/CN2016/073472 patent/WO2016127908A1/zh active Application Filing
- 2016-02-04 JP JP2017509728A patent/JP6510033B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104651300B (zh) | 2018-10-12 |
| CN104651300A (zh) | 2015-05-27 |
| WO2016127908A1 (zh) | 2016-08-18 |
| JP2017532008A (ja) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6510033B2 (ja) | 三次元複合細胞凝集体モデル並びにその製造方法及び応用 | |
| Zuppinger | 3D culture for cardiac cells | |
| Amano et al. | Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays | |
| JP7018635B2 (ja) | 立体的細胞組織の製造方法 | |
| Wu et al. | Acoustic assembly of cell spheroids in disposable capillaries | |
| Kapur et al. | Human adipose stem cells maintain proliferative, synthetic and multipotential properties when suspension cultured as self-assembling spheroids | |
| Valero et al. | Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device | |
| Desroches et al. | Functional scaffold-free 3-D cardiac microtissues: a novel model for the investigation of heart cells | |
| Li et al. | Microfluidic 3D cell culture: potential application for tissue-based bioassays | |
| McMurray et al. | Using biomaterials to study stem cell mechanotransduction, growth and differentiation | |
| Lin et al. | Recent advances in three‐dimensional multicellular spheroid culture for biomedical research | |
| Tsuda et al. | Heterotypic cell interactions on a dually patterned surface | |
| Li et al. | Three-dimensional perfused cell culture | |
| Lewis et al. | A quiescent, regeneration-responsive tissue engineered mesenchymal stem cell bone marrow niche model via magnetic levitation | |
| JP5725560B2 (ja) | 細胞シートを利用した細胞評価システム及びその利用方法 | |
| Palmiero et al. | Engineered dermal equivalent tissue in vitro by assembly of microtissue precursors | |
| Wang et al. | Advanced biomedical applications based on emerging 3D cell culturing platforms | |
| Wang et al. | A 3D construct of the intestinal canal with wrinkle morphology on a centrifugation configuring microfluidic chip | |
| Lippi et al. | Human cell modeling for cardiovascular diseases | |
| Zhang et al. | Flexible Fabrication of Shape‐Controlled Collagen Building Blocks for Self‐Assembly of 3D Microtissues | |
| Zhu et al. | Cardiac organoids: a 3D technology for modeling heart development and disease | |
| Mierke | Physical and biological advances in endothelial cell-based engineered co-culture model systems | |
| Aalders et al. | Liquid marble technology to create cost-effective 3D cardiospheres as a platform for in vitro drug testing and disease modelling | |
| He et al. | Modular assembly–based approach of loosely packing co-cultured hepatic tissue elements with endothelialization for liver tissue engineering | |
| Coffee et al. | Heart Muscle Tissue Engineering: Advantages and Challenges in Cardiac Microtissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170828 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180416 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181228 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190222 |
|
| TRDD | Decision of grant or rejection written | ||
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190220 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190312 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6510033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |